Gil-Ibañez Blanca, Gil-Moreno Antonio, Torné Aureli, Martín Jimenez Angel, Gorostidi Mikel, Zapardiel Ignacio, Tejerizo Garcia Alvaro, Diaz-Feijoo Berta
Gynecological Oncology and Minimally Invasive Surgery Unit, Department of Obstetrics and Gynecology, 12 de Octubre University Hospital, 28041 Madrid, Spain.
Gynecological Oncology Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Cancers (Basel). 2022 Apr 23;14(9):2108. doi: 10.3390/cancers14092108.
Background: The aim of this study was to analyze the impact of tumor size > 2 cm on oncological outcomes of fertility-sparing surgery (FSS) in early cervical cancer in a Spanish cohort. Methods: A multicenter, retrospective cohort study of early cervical cancer (stage IA1 with lymphovascular space invasion -IB1 (FIGO 2009)) patients with gestational desire who underwent FSS at 12 tertiary departments of gynecology oncology between 01/2005 and 01/2019 throughout Spain. Results: A total of 111 patients were included, 82 (73.9%) with tumors < 2 cm and 29 (26.1%) with tumors 2−4 cm. Patients’ characteristics were balanced except from lymphovascular space invasion. All were intraoperative lymph node-negative. Median follow-up was 55.7 and 30.7 months, respectively. Eleven recurrences were diagnosed (9.9%), five (6.0%) and six (21.4%) (p < 0.05). The 3-year progression-free survival (PFS) was 95.7% (95%CI 87.3−98.6) and 76.9% (95% CI 55.2−89.0) (p = 0.011). Only tumor size (<2 cm vs. 2−4 cm) was found to be significant for recurrence. After adjusting for the rest of the variables, tumor size 2−4 cm showed a Hazard Ratio of 5.99 (CI 95% 1.01−35.41, p = 0.036). Conclusions: Tumor size ≥ 2 cm is the most important negative prognostic factor in this multicenter cohort of patients with early cervical cancer and gestational desire who underwent FSS in Spain.
本研究旨在分析肿瘤大小>2 cm对西班牙队列中早期宫颈癌保留生育功能手术(FSS)肿瘤学结局的影响。方法:对2005年1月至2019年1月期间在西班牙12个三级妇科肿瘤科室接受FSS且有生育意愿的早期宫颈癌(IA1期伴脉管间隙浸润-IB1期(FIGO 2009))患者进行多中心回顾性队列研究。结果:共纳入111例患者,82例(73.9%)肿瘤<2 cm,29例(26.1%)肿瘤2-4 cm。除脉管间隙浸润外,患者特征均衡。所有患者术中淋巴结均为阴性。中位随访时间分别为55.7个月和30.7个月。诊断出11例复发(9.9%),分别为5例(6.0%)和6例(21.4%)(p<0.05)。3年无进展生存率(PFS)分别为95.7%(95%CI 87.3-98.6)和76.9%(95%CI 55.2-89.0)(p=0.011)。仅发现肿瘤大小(<2 cm与2-4 cm)对复发有显著影响。在对其他变量进行校正后,肿瘤大小2-4 cm的风险比为5.99(95%CI 1.01-35.41,p=0.036)。结论:在西班牙接受FSS且有生育意愿的早期宫颈癌多中心队列患者中,肿瘤大小≥2 cm是最重要的不良预后因素。